TECENTRIQ HYBREZA
RegisteredWord Mark
•
Ownership
GI
Owner Name
Type: Organization / Corporation
Address
1 DNA Way
South San Francisco, CA 94080
Critical Dates
First Use Date
Sep 30, 2024
Filing Date
Mar 30, 2022
Registration Date
Apr 29, 2025
Mark Descriptions
Goods
Class 5
Pharmaceutical preparations, applied subcutaneously and containing atezolizumab, for the treatment of oncological disorders and diseases
Mark Elements
Text Mark
TECENTRIQ HYBREZA
Category
Trademark
Standard Characters
Yes
Color Claim
No
Data source: USPTO TSDR
View on USPTO websiteTrademark Timeline
First Use
Filing Date
Publication Date
Registration Date
USPTO Records
| Title | Date | Category | Source | Pages | Format | Actions |
|---|---|---|---|---|---|---|
AI AssessmentCached Mar 12, 2026, 07:44 AMCached
AI-generated analysis of USPTO data for this trademark. WARNING: Content may not be accurate or up to date. Validate all responses.
Trademark Summary
TECENTRIQ HYBREZA is a standard character trademark covering pharmaceutical preparations applied subcutaneously and containing atezolizumab for the treatment of oncological disorders and diseases in class 005, with additional domestic classifications in classes 006, 018, 044, 046, 051, and 052. The mark is registered on the Principal Register (Reg. No. 7779001) effective April 29, 2025. It is owned by Genentech, Inc., a Delaware corporation located in South San Francisco, California. No oppositions or legal proceedings are present.
Recent Activity
The application was filed on March 30, 2022, published for opposition on May 30, 2023, and issued a Notice of Allowance on July 25, 2023. Following two extensions and a Statement of Use filed on January 22, 2025, the mark was accepted for registration on April 9, 2025, and registered on April 29, 2025.
USPTO
AI Analysis
v2.8.0
Never miss important updates for this trademark
Get instant alerts when status changes, similar marks are filed, or renewal deadlines approach